EyeGate randomizes first patients in punctate epitheliopathies study

EyeGate Pharmaceuticals has randomized the first three patients in a study of its Ocular Bandage Gel to reduce corneal staining in punctate epitheliopathies, the company announced in a press release.

Thirty-four subjects are currently in the qualification stage before randomization; subjects are still being enrolled in the study because 30 patients are needed for the treatment stage.

The Ocular Bandage Gel is also being studied in patients with large corneal defects due to PRK surgery, the release said. That study is more than 80% enrolled.

“As we continue to advance the OBG platform towards commercialization, we continue to actively consider all strategic alternatives to maximize shareholder value,” Stephen From, EyeGate CEO, said in the release.

EyeGate Pharmaceuticals has randomized the first three patients in a study of its Ocular Bandage Gel to reduce corneal staining in punctate epitheliopathies, the company announced in a press release.

Thirty-four subjects are currently in the qualification stage before randomization; subjects are still being enrolled in the study because 30 patients are needed for the treatment stage.

The Ocular Bandage Gel is also being studied in patients with large corneal defects due to PRK surgery, the release said. That study is more than 80% enrolled.

“As we continue to advance the OBG platform towards commercialization, we continue to actively consider all strategic alternatives to maximize shareholder value,” Stephen From, EyeGate CEO, said in the release.